All In Biotech

Drug Trial Radar · NCT06906731

A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors

An Open-label, Multicenter Phase I/II Study of Safety, Tolerability,Pharmacokinetics and Efficacy of SHR-9803 for Injection in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Apr 2025

Primary completion

Jun 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Apr 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multi-center, multiple doses Phase I/II study to evaluate the safety, tolerability ,pharmacokinetics and efficacy of SHR-9803 for injection in subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • SHR-9803Drug

    SHR-9803

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limited Toxicity(Ia)Time frame: Screening up to the end of phase Ia, an average of 6 months
  2. Dose Limited Toxicity (Ib)Time frame: Screening up to the end of phase Ib, an average of 1 year
  3. Recommended phase II dose(Ib)Time frame: Screening up to the end of phase Ib, an average of 2 years
  4. objective response rate(II)Time frame: Screening up to study completion, an average of 3 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Harbin Medical University cancer hospital

    Harbin, Heilongjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.